A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

NCT02182063 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: BIBF 1120 low dose
DRUG: BIBF 1120 high dose

Sponsor

Boehringer Ingelheim